Neurocrine Biosciences, Inc. (LON:0K6R)
London · Delayed Price · Currency is GBP · Price in USD 137.64
-10.63 (-7.17%)
At close: Oct 29, 2025
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,800 employees as of December 31, 2024. The number of employees increased by 400 or 28.57% compared to the previous year.
Employees
1,800
Change (1Y)
400
Growth (1Y)
28.57%
Revenue / Employee
1.11M GBP
Profits / Employee
176.89K GBP
Market Cap
10.47B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,800 | 400 | 28.57% |
| Dec 31, 2023 | 1,400 | 200 | 16.67% |
| Dec 31, 2022 | 1,200 | 300 | 33.33% |
| Dec 31, 2021 | 900 | 55 | 6.51% |
| Dec 31, 2020 | 845 | 145 | 20.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
Neurocrine Biosciences News
- 2 days ago - Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Neurocrine Biosciences Reports Third Quarter 2025 Financial Results - PRNewsWire
- 10 days ago - Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth - Nasdaq
- 10 days ago - Neurocrine Biosciences (NBIX): Citigroup Initiates Coverage with 'Buy' Rating | NBIX Stock News - GuruFocus
- 11 days ago - Morgan Stanley Raises Price Target for Neurocrine Biosciences (NBIX) | NBIX Stock News - GuruFocus
- 13 days ago - Neurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst Approaches - Seeking Alpha
- 14 days ago - Neurocrine Biosciences Announces Positive Data From Post-Hoc Analysis Of Tardive Dyskinesia Study - Nasdaq
- 14 days ago - Neurocrine (NBIX) Reports Promising Long-Term Efficacy of INGREZZA in Tardive Dyskinesia - GuruFocus